biotech
<a href="https://www.fiercebiotech.com/pharma/daiichi-sankyo-targets-global-top-5-oncology-rank-2035-13b-efficiency-drive-new-5-year-plan" hreflang="en">Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan</a>
FierceBiotech
May 11, 2026 · 1 min listen
Listen · FierceBiotech
<a href="https://www.fiercebiotech.com/pharma/daiichi-sankyo-targets-global-top-5-oncology-rank-2035-13b-efficiency-drive-new-5-year-plan" hreflang="en">Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan</a>
0:00-0:32
Live · Kokoro-82M
Audio pre-rendered by Storyflo · cached + delivered from the edge
Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five oncology player by 2035, plus a major $1.3 billion cost optimization initiative.
Share
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to FierceBiotech.
Heard via Storyflo
Get audio versions of every article you read.
Pick what matters — your audio curator gets you into your daily flo.